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Objective: Recent economic and health policy changes may have affected the ability of chronically ill patients to
afford their medications. We assessed changes in cost-related nonadherence to medication (CRN) before and after
the implementation of Medicare Part D in 2006.
Methods: We used data from the National Health Interview Survey, an annual, population-based survey of
community-dwelling, noninstitutionalized US adults, to estimate CRN in 8,673 stroke survivors aged 45 years or
older, representing 4.8 million survivors, for the years 1999 to 2010. The main outcome measure was CRN, defined
as self-reported inability to afford prescribed medication within the past 12 months.
Results: During the period 1999 to 2010, 11.4% of stroke survivors, approximately 543,000 individuals, reported
CRN. From 1999 to 2010, CRN more than doubled among stroke survivors aged 45 to 64 years (from 12.7 to 26.5%;
ptrend ¼ 0.01). CRN remained stable among those aged 65 years or older (from 3.8 to 7.0%; ptrend ¼ 0.21). From
1999–2005 to 2006–2010, CRN among uninsured stroke survivors aged 45 to 64 years increased from 43.1 to 57.1%
(p ¼ 0.03). Among stroke survivors aged 65 years or older with Medicare coverage, CRN was higher among
Medicare Part D participants than those without the drug benefit (7.9 vs 4.8%; p ¼ 0.02). After adjustment for
sociodemographic and clinical factors, CRN was similar among Medicare Part D enrollees and nonenrollees.
Interpretation: From 1999 to 2010, CRN increased significantly among stroke survivors younger than 65 years,
particularly among those without health insurance. There was no evidence that Medicare Part D decreased CRN
among stroke survivors with Medicare.
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The ability of chronically ill adults to afford theirmedications is a critical public health issue. Cost-
related nonadherence to medication (CRN) is associated
with recurrent vascular events, health declines, worse
quality of life, and death.1–3 Financial barriers contribute
to >60% of medication nonfulfillment and 45% of
medication nonpersistence among US adults with hyper-
tension or diabetes, 2 major cerebrovascular risk factors.4
In 2006, the US government implemented the
Medicare Part D drug benefit, which allowed Medicare-
covered adults to purchase insurance for prescription
drug coverage. This intervention aimed to reduce CRN
in older or disabled adults. However, the recent eco-
nomic downturn may have disproportionally worsened
CRN in chronically ill adults younger than 65 years,
because they are more likely to live in poverty, be unin-
sured, or have high out-of-pocket medical expenses.5–7
Stroke survivors represent an ideal group in which
to study the impact of Medicare Part D on reducing
CRN in chronically ill adults. Stroke is common in older
adults and is the leading cause of adult disability.8 By
2030, the United States is projected to have an
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additional 4 million stroke survivors, a 25% increase in
prevalence from 2010.9 Stroke survivors have a high risk
of cardiovascular events, including a 4 to 15% annual
risk of recurrent stroke.8 These complications increase
stroke patients’ morbidity, disability, and health care
costs.8,10 Randomized trials have demonstrated that
antithrombotic drugs, antihypertensive drugs, and
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors (statins) are effective in preventing further disability
and morbidity in stroke survivors,11–14 and as many as
80% of recurrent strokes may be prevented with pharma-
cotherapy.15 However, for stroke survivors, medications
may be inaccessible due to costs. Stroke survivors have
high prescription medication needs and costs16 and have
greater health-related financial burdens than patients with
other chronic diseases.17
Little is known about how recent policy and eco-
nomic changes may have affected the ability of US stroke
survivors to afford their medications over time. There-
fore, we assessed CRN by age and insurance, including
Medicare Part D, and across time in a national sample of
US stroke survivors. We hypothesized that, from 1999 to
2010, CRN increased in younger stroke survivors (aged
45–64 years), increased in the uninsured (aged 45–64
years), and decreased among Medicare patients with
access to the Part D drug benefit.
Patients and Methods
Data Source
The National Health Interview Survey (NHIS) is an ongoing,
household survey of the civilian, noninstitutionalized US popu-
lation conducted annually by the National Center for Health
Statistics (NCHS) using face-to-face interview.18 NHIS used
similar survey designs and data collection methods between
1999 and 2010, and sample adults had conditional response
rates of 74 to 84%.18 Data were obtained from the Integrated
Public Use Microdata Series (Minnesota Population Center and
State Health Access Data Assistance Center, Integrated Health
Interview Series; version 5.0, University of Minnesota) and the
NCHS.18 If the subject is physically or mentally unable to an-
swer the survey questions, then a knowledgeable proxy provides
answers (200–350 cases per year).18
Study Population
We identified stroke survivors as respondents who answered yes
to the question, ‘‘Have you ever been told by a doctor or other
health professional that you had a stroke?’’ The 1999–2010
NHIS sampled from all US states and the District of Columbia
and was designed to produce representative population-based
estimates for the entire United States.18 Of 8,752 NHIS
respondents aged 45 years or older reporting a physician diag-
nosis of stroke, we excluded 79 (0.9%) who did not provide
information on CRN, leaving 8,673 available for analysis.
Outcome Measure
CRN was defined by the answer to: ‘‘During the past 12
months, was there any time when you needed prescription
medicines, but didn’t get [them] because you couldn’t afford
[them]?’’ The inability to afford medications increases the
probability of stroke preventive medication underuse attrib-
utable to cost by more than 2-fold among stroke
survivors.19 Moreover, financial barriers increase the risk of
nonadherence to statins, antihypertensive medications, and
clopidogrel.20,21
Statistical Analysis
The frequency of CRN across individual years (1999–2010)
was compared using the Cochran–Mantel–Haenszel chi-square
test for trend, and US population-weighted estimates were cal-
culated. Analyses were conducted for the overall sample and
within 2 age strata (<65 vs 65 years), because US adults gen-
erally qualify for Medicare health insurance at age 65, and age
modifies access to medications among stroke survivors.22 In the
United States, stroke survivors younger than 65 years qualify
for Medicare health insurance if they have been receiving Social
Security or Railroad Retirement Board disability benefits for 2
or more years.23 Within each age stratum, we compared the
frequency of CRN by insurance and time before and after
Medicare Part D implementation (1999–2005 vs 2006–2010)
using Wald chi-square.
Respondent characteristics were compared between age
or insurance groups using Wald chi-square test or t test.
Covariates were selected based on literature review and the
Andersen Behavioral Model.24 Covariates included age, sex,
race (white, black, or other), Hispanic ethnicity, education
(<high school, high school, some college,  college), the ra-
tio of family income to poverty threshold (<1.0, 1.0–1.99,
2.00, missing/unreported), and health insurance (private
coverage with or without Medicare, Medicaid and Medicare,
Medicare only, other insurance, uninsured). Respondents also
reported whether they were enrolled in Medicare Part D dur-
ing the current survey year, which corresponds to the calen-
dar year. Medicare Part D coverage is assumed to be for the
entire year, because Medicare policy does not permit disen-
rollment from Medicare Part D during a calendar year.23
Self-reported health status was dichotomized as low (fair or
poor) or high (excellent, very good, or good). A comorbidity
score was calculated using a modified Charlson Index vali-
dated for use in stroke outcome studies.25 Functional disabil-
ity was defined as a health problem that led to difficulty
with 1 functional activity (eg, walking a quarter mile, lift-
ing/carrying 10 pounds).
Multivariable logistic regression analyses, stratified by the
2 age groups, were performed to examine the adjusted associa-
tions between insurance and time and the outcome measure,
CRN. Time was examined as a continuous variable or as a
binary variable (1999–2005 vs 2006–2010). We examined the
effect of sequential addition of factors to the models. We
obtained estimates and standard errors of predicted marginals
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after adjusting for covariates. All of the analyses used SAS-
callable SUDAAN version 9.01 (Research Triangle Institute,
Research Triangle Park, NC) to obtain proper variance
estimates that accounted for the complex NHIS sampling
design and results that were weighted to reflect national
population estimates.
TABLE 1: Characteristics of Stroke Survivors, by Age Group and Time: National Health Interview Survey,
1999–2010









No.; population estimate 1,687; 850,925 1,254; 874,267 3,572; 1,697,684 2,160; 1,348,079
Mean age, years (95% CI) 55.9 (55.6–56.2) 55.9 (55.5–56.2) 76.2 (75.9–76.4) 76.5 (76.1–76.8)
Female, % (95% CI) 48.4 (45.6–51.3) 50.7 (47.2–54.1) 54.6 (52.7–56.4) 55.0 (52.4–57.6)
Race, % (95% CI)
White 74.7 (72.2–77.1) 76.3 (73.5–78.8) 86.1 (84.7–87.3) 83.8 (82.2–85.3)
Black 18.2 (16.2–20.4) 17.9 (15.6–20.5) 9.8 (8.8–10.9) 11.6 (10.4–13.0)
Other 7.1 (5.7–8.8) 5.8 (4.3–7.9) 4.2 (3.5–5.1) 4.6 (3.7–5.6)
Hispanic ethnicity,
% (95% CI)
8.2 (7.0–9.5) 10.2 (8.5–12.2) 5.8 (5.0–6.8) 5.7 (4.8–6.7)
Education, % (95% CI)
<High school 27.3 (24.9–29.8) 22.4 (19.6–25.3) 38.6 (36.7–40.5) 32.5 (30.1–35.0)
High school 36.0 (33.3–38.7) 32.3 (28.9–35.9) 31.1 (29.4–32.9) 32.0 (29.6–34.5)
Some college 24.7 (22.4–27.2) 31.4 (28.2–34.8) 17.7 (16.3–19.1) 20.6 (18.7–22.8)
College 12.0 (10.2–14.0) 13.9 (11.5–16.7) 12.7 (11.4–14.0) 14.9 (13.0–16.9)
Insurance, % (95% CI)
Private and Medicare 6.3 (5.0–8.0) 6.6 (5.1–8.6) 54.5 (52.6–56.4) 51.8 (49.1–54.4)
Private only 44.3 (41.6–47.1) 39.2 (35.8–42.6) 4.0 (3.3–4.9) 1.7 (1.1–2.6)
Medicare only 10.9 (9.3–12.7) 13.1 (10.8–15.7) 24.8 (23.2–26.5) 27.7 (25.5–30.1)
Other 27.9 (25.5–30.4) 29.4 (26.4–32.6) 15.8 (14.5–17.1) 18.3 (16.5–20.2)
Uninsured 10.6 (9.0–12.5) 11.8 (9.9–14.0) 1.0 (0.6–1.7) 0.5 (0.3–1.1)
Any Medicare insurance 25.8 (23.4–28.3) 29.5 (26.4–32.8) 92.9 (91.8–93.9) 96.4 (95.3–97.3)
Family income to poverty
ratio, % (95% CI)
<1.00 17.4 (15.5–19.4) 19.9 (17.6–22.4) 9.3 (8.3–10.3) 10.0 (8.8–11.3)
1–1.99 19.3 (17.2–21.6) 22.9 (20.1–26.0) 22.1 (20.6–23.7) 22.0 (19.9–24.2)
2.00 40.5 (37.8–43.3) 46.7 (43.3–50.2) 36.1 (34.3–38.0) 45.4 (42.8–47.9)
Missing or unreported 22.8 (20.5–25.2) 10.5 (8.6–12.7) 32.6 (30.8–34.4) 22.7 (20.6–25.0)
Low health status, % (95% CI) 59.2 (56.4–61.9) 57.9 (54.5–61.3) 52.2 (50.2–54.1) 48.8 (46.3–51.4)
Functional disability, % (95% CI) 78.7 (76.2–80.9) 79.4 (76.3–82.2) 84.8 (83.4–86.1) 86.4 (84.5–88.0)
Mean modified Charlson
comorbidity score, % (95% CI)
1.58 (1.50–1.67) 1.83 (1.73–1.94) 1.71 (1.65–1.76) 2.06 (1.99–2.13)
Analyses accounted for the complex sampling design and used proper variance estimations to produce results that were weighted
to reflect national population estimates.
CI ¼ confidence interval.
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Standard Protocol Approvals, Registrations,
and Patient Consents
The University of Michigan Institutional Review Board ruled
the project exempt.
Results
The sample included 8,673 stroke survivors aged 45
years, representing an estimated 4.8 million US stroke
survivors. Among all stroke survivors aged 45 years or
older, the proportion who were aged 45 to 64 years
increased from 33.4% in 1999–2005 to 39.3% in 2006–
2010 (p < 0.001). From 1999–2005 to 2006–2010,
educational attainment, the family income to poverty
ratio, and mean comorbidity score increased among
stroke survivors above and below age 65 years (Table 1).
From 1999–2005 to 2006–2010, the proportion of
stroke survivors aged 65 years or older with Medicare in-
surance increased from 92.9 to 96.4% (p < 0.001).
Between 2006 and 2010, we identified 2,083 stroke sur-
vivors aged 65 years or older with Medicare representing
an estimated 1.3 million survivors, and 377 stroke survi-
vors aged 45 to 64 years with Medicare representing an
estimated 257,000 survivors. The proportion of stroke
survivors with Medicare who reported Medicare Part D
coverage was 50.5% in the age 45 to 64 years group and
39.7% in the age 65 years and older group. Among
younger or older stroke survivors, Medicare Part D
enrollees more frequently were women and had less edu-
cation, lower income, and poorer health status than non-
enrollees; in addition, Medicare Part D enrollees were
more likely to have Medicaid insurance but less likely to
have private insurance (Supplementary Table 1). Among
the stroke survivors who were dually eligible for Medi-
care and Medicaid, 38% of those aged 45 to 64 years
and 16% of those aged 65 years or older reported
Medicare Part D coverage.
Temporal Trends in CRN Overall and by Age
During the period from 1999 to 2010, 11.4% of stroke
survivors, representing approximately 543,000 individu-
als, reported CRN. Among stroke survivors aged 45 years
or older, the prevalence of CRN increased from 6.5% in
1999 to 15.4% in 2010 (ptrend < 0.001). From 1999 to
2010, the percentage of stroke survivors reporting CRN
increased from 12.7 to 26.5% (ptrend ¼ 0.01) among
those aged 45 to 64 years, and CRN increased nonsigni-
ficantly among those aged 65 years or older (from 3.8 to
7.0%; ptrend ¼ 0.21; Fig). After adjustment for sociode-
mographics, clinical factors, and insurance, CRN did not
increase significantly over the study period in those aged
45 to 64 years (ptrend ¼ 0.08) or those aged 65 years or
older (p ¼ 0.90; see Fig and Supplementary Table 2).
Greater odds of CRN were associated with female gen-
der, no health insurance, greater poverty, lower health
status, more functional limitations, and higher comorbid-
ity score (all p < 0.01).
Temporal Trends in CRN by Insurance Status
Within the 45 to 64 years age group, rates of CRN
increased among uninsured individuals (from 43.1% in
1999–2005 to 57.1% in 2006–2010; p ¼ 0.03) and
those with private insurance (from 8.6 to 13.6%; p ¼
0.047); however, CRN remained stable among those
with Medicare only or other insurance (Table 2). Among
stroke survivors aged 65 years or older, CRN rates
remained stable from 1999–2005 to 2006–2010 within
each insurance group (Table 3). Sample size precluded
subgroup analyses of temporal trends in CRN among
younger adults with private and Medicare insurance and
among older adults with private insurance only or no
health insurance.
Among all stroke survivors aged 45 years or older
with Medicare insurance, Medicare Part D enrollees
more frequently reported CRN than nonenrollees (11.6
vs 6.6%; p < 0.001). Among those aged 65 years or
older, CRN was higher among Medicare Part D
FIGURE : Percentage of US stroke survivors who did not
get needed prescription drugs because of cost, by age
group and year, before and after adjustment: National
Health Interview Survey, 1999–2010. Adjusted for sex, race,
Hispanic ethnicity, education, insurance, family income to
poverty level ratio, health status, modified Charlson comor-
bidity score, and functional disability. p 5 0.01 for trend
over time (chi-square test) from unadjusted model for age
group 45 to 64 years. p 5 0.21 for trend over time (chi-
square test) from unadjusted model for age group 65
years. p 5 0.08 for trend over time (chi-square test) from
fully adjusted model for age group 45 to 64 years. p 5 0.90
for trend over time (chi-square test) from fully adjusted
model for age group 65 years. Analyses accounted for the
complex sampling design and used proper variance estima-
tions to produce results that were weighted to reflect
national population estimates.
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participants than those without the drug benefit (7.7 vs
4.5%; p ¼ 0.01). In the smaller group of stroke survivors
younger than 65 years with Medicare coverage, similar
albeit nonsignificant CRN differences between Medicare
Part D enrollees and nonenrollees were seen (27.0 vs
19.4%; p ¼ 0.20). After adjustment for sociodemo-
graphics, clinical factors, and insurance, CRN was similar
among Medicare Part D enrollees and nonenrollees
(Table 4).
Discussion
In this nationally representative sample, 11% of stroke
survivors, an estimated 543,000 individuals, experienced
CRN during the period of 1999–2010. CRN increased
significantly among stroke survivors aged 45 to 64 years
from 1999–2005 to 2006–2010, particularly among
those with no health insurance (from 43 to 57%). CRN
remained relatively stable among stroke survivors aged 65
years and older. Among older stroke survivors with Med-
icare coverage, CRN was 2-fold greater among Medicare
Part D enrollees than those without the drug benefit.
Although differences in sociodemographics, clinical fac-
tors, and health insurance between Medicare Part D
enrollees and nonenrollees explained this apparent para-
dox, our results demonstrate that Medicare Part D has
not solved the problem of CRN for many stroke
survivors.
CRN was more common among older stroke survi-
vors who enrolled in Medicare Part D than those who
did not. This apparent paradox may be explained by the
characteristics of early Medicare Part D adopters.
TABLE 2: Proportion (and Standard Error) of Stroke Survivors Aged 45 to 64 Years Not Able to Afford
Prescription Medication, by Insurance Group and Time: National Health Interview Survey, 1999–2010
Insurance Type Unadjusted Proportions
(SE), n ¼ 2,765
p Adjusted Proportions











Private insurance only 0.09 (0.01) 0.14 (0.02) 0.12 (0.02) 0.18 (0.03)
Medicare only 0.34 (0.04) 0.32 (0.05) 0.29 (0.04) 0.24 (0.04)
Other 0.18 (0.02) 0.18 (0.02) 0.15 (0.02) 0.14 (0.02)
Uninsured 0.43 (0.04) 0.57 (0.05) 0.47 (0.04) 0.52 (0.05)
Adjusted proportion is predicted marginals after adjusting for sex, race, Hispanic ethnicity, education, family income to poverty
level ratio, health status, modified Charlson comorbidity score, and functional disability. Observations with missing data were
excluded from the regression models. Sample size precluded subgroup analysis in younger adults with private and Medicare
insurance. Analyses accounted for the complex sampling design and used proper variance estimations to produce results that were
weighted to reflect national population estimates.
SE ¼ standard error.
TABLE 3: Proportion (and Standard Error) of Stroke Survivors Aged 65 Years or Older Not Able to Afford
Prescription Medication, by Age Group and Time: National Health Interview Survey, 1999–2010
Insurance Type Unadjusted Proportions
(SE), n ¼ 5,155
p Adjusted Proportions











Private and Medicare 0.04 (0.01) 0.04 (0.01) 0.05 (0.01) 0.04 (0.01)
Medicare only 0.10 (0.01) 0.10 (0.01) 0.10 (0.01) 0.09 (0.01)
Medicare and Medicaid 0.10 (0.02) 0.10 (0.02) 0.06 (0.01) 0.05 (0.01)
Adjusted proportion is predicted marginals after adjusting for sex, race, Hispanic ethnicity, education, family income to poverty
level ratio, health status, modified Charlson comorbidity score, and functional disability. Observations with missing data were
excluded from the regression models. Sample size precluded subgroup analysis in older adults with private insurance only or no
health insurance. Analyses accounted for the complex sampling design and used proper variance estimations to produce results that
were weighted to reflect national population estimates.
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Compared to those who did not enroll, the stroke survi-
vors who enrolled in Medicare Part D more frequently
reported risk factors for CRN,22 including less education,
poor health status, low income, and less private insurance
coverage, similar to other reports.26,27 After accounting
for these differences, CRN did not differ by Medicare
Part D enrollment. However, our results show that CRN
remains high for a substantial portion of older adults
with stroke, despite the Medicare Part D drug benefit.
Given that Medicare Part D is associated with
small, but significant, reductions in CRN,28,29 it is possi-
ble that the positive effects of Medicare Part D on CRN
mitigated the negative effects of the economic recession
and the rising use and costs of medications, thus result-
ing in relatively stable prevalence of CRN among the
older stroke survivors in our study. Another explanation
is that the drug benefit may be less effective at reducing
CRN among the sickest beneficiaries who have persis-
tently elevated rates of CRN.28,29 This observation may
partly explain why the older stroke survivors with Medi-
care coverage in our study had stable, not decreased,
CRN after Medicare Part D implementation. Further-
more, stroke survivors enrolled in Medicare Part D still
have high out-of-pocket expenditures due to rising Medi-
care Part D drug prices30 or reaching the ‘‘doughnut
hole,’’ a gap in prescription drug coverage occurring in
nearly half of patients taking medication for stroke or
myocardial infarction.27 Although the Affordable Care
Act would reduce Part D enrollees’ drug costs in the gap
using federal and manufacturer subsidies and by lowering
the limit for catastrophic coverage, it is unknown how
these changes will impact CRN in stroke survivors.
Our findings also suggest potential underutilization
of Medicare Part D, particularly by chronically ill adults
living in poverty. Of stroke survivors who were Medicare
beneficiaries, only half of those aged 45 to 64 years and
40% of those aged 65 years or older reported Medicare
Part D coverage. These percentages are consistent with
previous reports of Medicare Part D coverage by 38% of
older adults in an ongoing, longitudinal, biracial popula-
tion-based study and by 50% of older adults in a
national sample of noninstitutionalized Medicare benefi-
ciaries.26,31 Some NHIS respondents may have been
unaware of their eligibility for Medicare Part D coverage.
For example, the Centers for Medicare and Medicaid
Services assigned adults eligible for both Medicare and
Medicaid to Part D prescription drug plans. However,
among the dually eligible adults in our study, only 38%
of those aged 45 to 64 years and 16% of those aged 65
years or older reported Medicare Part D enrollment.
Taken together, these data suggest a missed educational
opportunity for Medicare Part D and low-income
subsidy participation.26,31
Adults younger than 65 years with chronic illness
have substantial financial burdens for health care.5,17
This problem may be worse among stroke patients, given
that the average US stroke survivor takes 11 different
medications (range, 3–27 medications),16 and prescrip-
tion medication accounts for 35 to 50% of total out-of-
pocket medical expenses.17 In 2003, approximately 55%
TABLE 4: Proportion (and Standard Error) of Stroke Survivors with Medicare Insurance Not Able to Afford
Prescription Medication, by Age Group and Medicare Part D Status: National Health Interview Survey,
2006–2010














Unadjusted 0.27 (0.04) 0.19 (0.04) 0.20 0.08 (0.01) 0.04 (0.01) 0.01
Partially adjusted: all except
health insurance
0.25 (0.04) 0.21 (0.04) 0.54 0.07 (0.01) 0.05 (0.01) 0.09
Fully adjusted: includes
health insurance
0.25 (0.04) 0.24 (0.05) 0.96 0.07 (0.01) 0.06 (0.01) 0.35
Partially adjusted proportion is predicted marginals after adjusting for sex, race, Hispanic ethnicity, education, family income to
poverty level ratio, health status, modified Charlson comorbidity score, and functional disability. Fully adjusted proportion also
included health insurance (private, Medicaid, or neither). Observations with missing data were excluded from the regression mod-
els. Analyses accounted for the complex sampling design and used proper variance estimations to produce results that were
weighted to reflect national population estimates.
SE ¼ standard error.
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of stroke survivors younger than 65 years spent >10% of
family income on health care and about 30% of stroke
survivors spent >20% of family income on health care.17
Potential explanations of a more significant problem
affording medication in younger stroke survivors include
differences in competing household costs (eg, mortgage/
rent and childcare) or insurance cost-sharing, which
could not be assessed directly in our analysis.
Among uninsured stroke survivors younger than 65
years, we found that the high rates of CRN increased
further during the recession, when nearly 6 in 10 stroke
survivors were unable to afford prescription medications.
Changes in income and number of medications among
this group may partially explain this trend, because the
temporal increase in CRN was diminished after adjusting
for income, health status, and comorbidity. The Afford-
able Care Act is expected to reduce the number of unin-
sured adults through Medicaid expansion and subsidized
health insurance, even for those with pre-existing condi-
tions like stroke.32 However, our study and others26,28,33
suggest that insurance coverage alone likely will not elim-
inate CRN or its negative effect on disease control in
chronically ill adults.
Despite federal and local programs, medication is
still unaffordable for many stroke survivors. Temporal
increases in the number and cost of stroke preventive
medications potentially increased the cost of adherence
for stroke patients. During the study period, there were
significant increases in the prescription of antithrombotic
agents (aspirin-extended release dipyridamole34 and clo-
pidogrel34,35) and statins36 to stroke survivors. Although
less is known about trends in the prescription of high-
cost antihypertensive agents like ramipril to stroke survi-
vors, the use of angiotensin-converting enzyme inhibitors
or angiotensin II receptor blockers increased from 39 to
69% in survivors of acute myocardial infarction, a related
vascular disease, between 1997 and 2006.37
Newer antithrombotic drugs are efficacious in pre-
venting stroke in patients with nonvalvular atrial fibrilla-
tion,38–40 but the drugs’ costs will increase the cost of ad-
herence for stroke patients. The 2 available drugs,
dabigatran and rivaroxaban, each cost $8.50/day
(www.costco.com). Dabigatran prescriptions have soared,
with most prescriptions being for primary or secondary
stroke prevention.35 Because dabigatran has a shorter
half-life than warfarin, its benefit and cost-effectiveness
will be reduced in nonadherent patients.41,42 Although
the effect of CRN on health outcomes in stroke patients
could not be assessed directly in our current study, non-
adherence to secondary preventive medications increases
the risk of recurrent vascular events and death in myocar-
dial infarction patients3,43 and stroke patients.44,45
Our study has several limitations. The NHIS
includes only community-dwelling, noninstitutionalized
stroke survivors, and results may only be generalized to
this population. These self-reported NHIS data, includ-
ing stroke history, may lead to misclassification. Although
clinical information of stroke history was not available,
recent reports suggest high self-reported stroke accuracy,
even in the disabled elderly, with sensitivity rates ranging
from 80 to 98%.46,47
Proxy reports may over- or underestimate medica-
tion adherence. Although self-report measures can be
biased by inaccurate recall or by social desirability (ie,
individuals overestimate or inflate adherence),48 patient
self-report of medication nonadherence agrees with phar-
macy claims data49 and is strongly associated with
adverse events, including stroke and death, among adults
with known cardiovascular disease.1–3
The NHIS does not include provider characteristics
(eg, prescribing behavior or knowledge of patients’ ability
to pay) or patient-level information on the number and
costs of medications, pill counts, pharmacy claims, and
the magnitude or severity of CRN (ie, the number or
type of medications foregone due to cost). Although the
NHIS does not ascertain the number of medications, we
included a proxy variable, number of conditions. In addi-
tion, the NHIS measure of CRN does not include taking
fewer pills than prescribed, so our CRN estimates may
be low. The comorbidity score did not include disease se-
verity, acquired immunodeficiency syndrome, or periph-
eral vascular disease and so may underestimate comorbid-
ity. The effect of temporal changes in the number or cost
of medications on CRN in stroke survivors cannot be
assessed in these NHIS data.
In conclusion, we found that CRN increased signif-
icantly between 1999–2005 and 2006–2010 among
younger stroke survivors, particularly those who were
uninsured. There was no evidence that Medicare Part D
coverage decreased CRN among stroke survivors during
this time period. There were a considerable number of
stroke survivors who were unaware of their eligibility for
Medicare Part D.
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